20-F: Ascentage Pharma Files Annual 20-F Report

Ascentage Pharma Group International filed its annual report on Form 20-F for the fiscal year ended December 31, 2025, detailing its financial performance, clinical pipeline, and strategic outlook.

Summary

• Ascentage Pharma Group International has filed its annual report on Form 20-F for the fiscal year ended December 31, 2025.
• The report provides a comprehensive overview of the company's financial health, operational activities, and strategic direction.
• Key highlights include updates on its lead drug candidates, Olverembatinib and Lisaftoclax, and their ongoing clinical trials.
• The company reported a net loss of RMB1,243.0 million (US$177.7 million) for the year ended December 31, 2025, an increase from the previous year.
• Ascentage Pharma continues to invest heavily in research and development, with R&D expenses representing 61.0% of total operating expenses for 2025.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the significant increase in net loss and decrease in revenue, despite progress in clinical development and financing activities. The substantial R&D investment and ongoing need for future financing present considerable financial risks.

Positives

• Olverembatinib received inclusion in China's 2022 National Reimbursement Drug List (NRDL) effective March 1, 2023, and was further included in the 2024 National Comprehensive Cancer Network (NCCN) USA guidelines for CML management.
• Lisaftoclax received NMPA approval in China for CLL/SLL in July 2025, marking it as the first Bcl-2 inhibitor approved for this indication in China and the second globally.
• The company has a robust pipeline with multiple clinical-stage assets targeting hematological malignancies and solid tumors.
• Ascentage Pharma has established significant collaborations with leading biotechnology and pharmaceutical companies, including Innovent, AstraZeneca, Merck, and Pfizer.
• The company's manufacturing facility in Suzhou is EU GMP compliant, supporting global expansion efforts.
• Significant progress was made in advancing clinical trials for Olverembatinib (POLARIS-1, POLARIS-2, POLARIS-3) and Lisaftoclax (GLORA, GLORA-2, GLORA-3, GLORA-4) across multiple global regions.
• The company secured substantial financing through its U.S. IPO in January 2025 and a placing in July 2025, strengthening its liquidity position.

Negatives

• The company incurred a net loss of RMB1,243.0 million (US$177.7 million) for the year ended December 31, 2025, and has accumulated losses of RMB7,013.3 million (US$1,002.9 million) as of that date.
• Ascentage Pharma expects to continue incurring significant expenses and operating losses for the foreseeable future due to ongoing R&D and commercialization efforts.
• The company will need to obtain substantial additional financing to fund future operations and complete the development and commercialization of its drug candidates.
• Raising additional capital may cause dilution to existing shareholders, restrict operations, or require relinquishing rights to current or future products.
• The company faces significant competition from major pharmaceutical and biotechnology companies with greater financial resources and expertise.
• The company has a limited history of generating revenues from product sales outside of China, making future performance prediction uncertain.
• The company's reliance on third-party manufacturers and clinical trial organizations introduces risks related to supply, quality, and timely execution.

Risks

• The company has incurred significant net losses and expects to continue doing so, potentially impacting its ability to achieve or sustain profitability.
• Failure to obtain additional financing could prevent the company from completing the development and commercialization of its drug candidates.
• Clinical trials are inherently uncertain, and failure to demonstrate safety and efficacy could lead to delays or inability to commercialize drug candidates.
• Regulatory approval processes are lengthy, unpredictable, and may require additional studies, increasing costs and delaying market entry.
• The company is substantially dependent on the commercial success of Olverembatinib and Lisaftoclax, and failure to maintain or increase sales would adversely affect revenue.
• The company has limited commercialization experience, particularly outside of China, and may lack the necessary expertise and resources for successful global commercialization.
• Intellectual property protection is crucial, and competitors could develop and commercialize similar technologies or drugs if patent protection is inadequate.
• Reliance on third parties for manufacturing and clinical trials poses risks if these parties fail to meet quality standards or deadlines.
• Doing business in the PRC involves risks related to regulatory oversight, data security, and geopolitical tensions between the U.S. and China.
• The dual listing of ordinary shares and ADSs may affect liquidity and value, and potential delisting from Nasdaq due to HFCAA compliance issues is a risk.
• The trading prices of the ADSs have been and are likely to be volatile, which could result in substantial losses to investors.
• Failure to maintain an effective system of internal controls over financial reporting could lead to inaccurate reporting, fraud, and negatively impact investor confidence.
• Changes in U.S. healthcare laws and regulations, including pricing and reimbursement policies, could materially affect the business and results of operations.
• The company's operations and manufacturing facilities are subject to stringent and evolving regulations, and non-compliance could lead to sanctions or withdrawal of approvals.
• The company's reliance on its proprietary technologies and drug candidates is subject to the risks of patent challenges, circumvention, and expiration.
• The company may be subject to claims challenging the inventorship or ownership of its intellectual property.
• The company may face difficulties in obtaining necessary rights for its development pipeline through acquisitions and in-licenses.
• The company is subject to stringent and often unsettled laws, regulations, policies and contractual obligations related to privacy, data protection, and information security.
• The company faces uncertainties with respect to its leased properties in the PRC, including unregistered lease agreements and potential non-compliance issues.
• The company is subject to PRC regulations regarding employee benefit plans and other employment practices, and non-compliance could lead to penalties.
• Recent greater oversight by China's Cyberspace Administration (CAC) over data security could limit capital raising activities.
• The inability of the PCAOB to inspect auditors in China could lead to delisting from Nasdaq under the Holding Foreign Companies Accountable Act.
• The company may be restricted from transferring its scientific data abroad due to PRC regulations.
• Changes in economic, political or social conditions or government policies in China could adversely affect the business.
• The PRC legal system is evolving, and failure to comply with laws and regulations could have a material adverse effect.
• The voting rights of ADS holders are limited, and the depositary may vote at its discretion if instructions are not received.
• The company is a foreign private issuer and exempt from certain U.S. reporting requirements, potentially affording less information to investors.
• The company may lose its foreign private issuer status, leading to significant additional costs and expenses.
• The company reports financial results under IFRS, which differs from U.S. GAAP, potentially hindering comparability.
• The company is an emerging growth company and may take advantage of reduced reporting requirements, potentially limiting investor information.
• The company has experienced increased costs as a public company and expects these costs to increase further.
• The company's corporate governance practices may differ from U.S. domestic issuers, potentially affording less protection to shareholders.

Future Outlook

The company expects to continue incurring significant expenses and operating losses for the foreseeable future due to ongoing research and development activities, clinical trials, regulatory approvals, and the establishment of sales and marketing infrastructure. Future funding will likely come from equity sales, debt financings, collaborations, and strategic alliances. The company believes its current cash and bank balances, along with its loan facility, will fund operations for at least the next 12 months, but may not be sufficient to fund drug candidates through regulatory approval.

Management Comments

• Ascentage Pharma entered an accelerated commercialization phase driven by a dual-engine strategy: Olverembatinib achieved substantial growth following the implementation of NRDLs, while the newly launched Lisaftoclax rapidly scaled following its initial launch during 2025.
• Throughout 2025, the Company rapidly expanded its commercial footprint, further strengthened its commercialization capabilities, and continued to grow its in-house sales team.
• At the same time, the Company remained focused on enhancing product competitiveness through clinical value and evidence-based data, laying a solid foundation for sustainable long-term growth.
• Our in-house commercial team, which includes sales, marketing, market access, channel management, sales force effectiveness and sales training, includes more than 270 members, the vast majority of whom possess extensive professional experience in hematology-oncology field.
• For our two core products, the Company adopted a specialized, product-dedicated organizational structure.
• With the continued expansion of the commercial team and capabilities, we progressed from single-product commercialization to a dual-engine parallel strategy, supporting sustained growth of our cornerstone product, Olverembatinib, and the rapid uptake of the new launched product, Lisaftoclax.
• In 2025, our commercial team covered more than 1,500 hospitals and over 800 pharmacies for our two commercialized products.
• We also established strategic partnerships with leading pharmaceutical distributors, achieving national wide drug distribution coverage.
• We have established our own Suzhou facility as our global R&D center and manufacturing facility.
• Our Global Manufacturing Center and quality management system implemented at the site are compliant with the standards of the EU GMP, marking the achievement of a major milestone that will pave the way for our continued global expansion.

Industry Context

StockSavvy.ai notes that Ascentage Pharma operates in the highly competitive biopharmaceutical sector, focusing on hematological malignancies. The company's strategy involves leveraging its proprietary drug discovery platform and integrated capabilities to develop novel therapies for challenging targets. The market for hematological malignancies is substantial and growing, driven by an aging population and advancements in treatment. Ascentage Pharma's lead assets, Olverembatinib and Lisaftoclax, address significant unmet medical needs in CML, CLL, AML, and MDS, with Olverembatinib already commercialized in China and Lisaftoclax recently approved.

Comparison to Industry Standards

• Olverembatinib is positioned as a third-generation TKI, aiming to overcome resistance issues seen with earlier generations, particularly the T315I mutation, where it shows strong clinical activity.
• Lisaftoclax, a Bcl-2 inhibitor, demonstrates potential for combination therapies and a favorable pharmacokinetic profile, addressing unmet needs in CLL/SLL and AML.
• The company's pipeline includes other novel agents targeting pathways like MDM2-p53, PRC2, and FAK, reflecting industry trends towards targeted therapies and protein degraders.
• Ascentage Pharma's R&D expenses as a percentage of total operating expenses (61.0% in 2025) are consistent with or higher than many clinical-stage biopharmaceutical companies, indicating a strong commitment to innovation.
• The company's global clinical trial presence across Australia, Canada, China, Europe, Japan, the UK, India, and the US aligns with industry best practices for drug development and regulatory submissions.

Legal Proceedings

• The company is not currently a party to any litigation that, if determined adversely, would have a material adverse effect on its business, operating results, cash flows, or financial condition.

Related Party Transactions

• HealthQuest Acquisition: A RMB20.0 million (US$2.8 million) milestone payment was made to Dr. Yifan Zhai in June 2025 related to the acquisition of Healthquest Pharma.
• Tax Reimbursement: Ascentage Pharma reimbursed Dr. Dajun Yang US$553,648 for tax liabilities incurred in connection with the July 2025 placing.
• Concert Party Confirmation Deed: Key shareholders and founders (Yang, Zhai, Wang, Guo) have agreed to cooperate and communicate to maintain consolidated control and management of the company, voting unanimously on matters.
• Deed of Non-Competition: Key shareholders and founders agreed not to engage in competing business activities without offering the opportunity to the company first.

Stakeholder Impact

• Shareholders may experience dilution due to future equity financings and potential volatility in share price.
• Employees may benefit from equity incentives (RSUs and options) tied to company performance and growth.
• Creditors and lenders may be impacted by the company's financial performance and its ability to service debt, as indicated by its net losses and need for financing.
• Partners and collaborators (e.g., Innovent, Takeda) are subject to the terms of their agreements, with potential impacts on revenue streams and development timelines.
• Patients may benefit from the development and potential commercialization of new therapies for hematological malignancies, with Olverembatinib and Lisaftoclax already available in China.

Next Steps

• Continue advancing clinical development of Olverembatinib and Lisaftoclax in global registrational trials.
• Seek regulatory approvals for Olverembatinib and Lisaftoclax in markets outside of China.
• Expand commercialization capabilities and sales teams for Olverembatinib and Lisaftoclax in China.
• Continue R&D activities for other pipeline candidates, including APG-5918, APG-2449, APG-3288, and APG-115.
• Explore potential strategic partnerships and collaborations to advance drug development and commercialization.
• Manage financial resources and seek additional financing to support ongoing operations and future growth.

Key Dates

Recommendation

Ascentage Pharma's 20-F filing indicates significant progress in its clinical pipeline and financing activities, which are positive developments. However, the substantial increase in net loss, decrease in revenue, and continued reliance on external financing present considerable financial risks. The company's ability to successfully navigate regulatory hurdles and achieve commercial success for its drug candidates outside of China remains a key challenge. Given the mixed signals of pipeline advancement against financial headwinds, a 'hold' recommendation is appropriate, pending further clarity on clinical trial outcomes and future financing success.

Keywords

Ascentage Pharma, Form 20-F, Annual Report, Olverembatinib, Lisaftoclax, CML, CLL, AML, Hematological Malignancies, Oncology, Biopharmaceutical, Clinical Trials, FDA, NMPA, SEC Filing, SEC, Nasdaq, HKEx, Drug Development, Pharmaceuticals